Cipla down 4% on USFDA observations for three Goa facilities

Shares of drug firm Cipla today fell nearly 4 per cent after the company said the US health regulator has issued four observations across its three manufacturing facilities in Goa after the inspection.
The stock went down 3.44 per cent to settle at Rs 580.25 on BSE. During the day, it slipped 6.46 per cent to Rs 562.05.
At NSE, shares of the company fell 3.78 per cent to end at Rs 580.05.
The stock was the worst performer among the Sensex and Nifty scrips.
On the volume front, 8.51 lakh shares of the company were traded on BSE and over 69 lakh shares changed hands at NSE during the day.

"United States Food and Drug Administration (USFDA) recently concluded audit of our three manufacturing facilities in Goa and has issued four observations across these three facilities," Cipla said in a filing to BSE.
These observations were primarily procedural in nature and the company has already responded to the same, it added.
The company, however, did not provide any details of the observations.